Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT03501875 |
| Other study ID # |
P170703J |
| Secondary ID |
2017-A02904-49 |
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
May 15, 2018 |
| Est. completion date |
June 28, 2021 |
Study information
| Verified date |
September 2021 |
| Source |
Assistance Publique - Hôpitaux de Paris |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder characterized by
elevated plasma levels of LDL-C cholesterol. This early and significant elevation of LDL-C
triggers premature atherosclerosis, particularly coronary artery disease.
The initiation and management of LDL-C therapies is based on cardiovascular risk assessment.
Although this is undoubtedly higher than in normocholesterolemic patients, a significant
heterogeneity in heFH patients still persists that is not completely explained. Moreover, the
evaluation of cardiovascular risk in patients with heFH is difficult for many reasons:
non-validity of risk scores, futility of a risk calculation limited to 10 years in a young
patient, late positivity of stress tests .
Therefore, there is a clear need for new cardiovascular risk assessment tools to identify
higher risk heFH patients who could benefit from early and aggressive treatment.
The Coronary Artery Calcium (CAC) Score has been widely studied in the US and validated in
European recommendations, and has shown the best reclassification index for patients at
intermediate cardiovascular risk. A CAC score of zero is associated with a very low risk of
event irrespective of the number of risk factors.
Non-calcified plaques are by definition not detected by ACC and patients with CAC = 0 may
only have soft non-calcified plaques. The prevalence of these non-calcified plaques in very
high-risk patients with acute coronary syndrome is 5%. The prevalence in FH patients is
unknown. It has also been shown that the extent of the atherosclerotic burden is related to
cardiovascular risk.
CAC score has been poorly evaluated in heFH patients. However, hypercholesterolemia and
calcifications have been shown to be correlated: supra-aortic calcified masses in homozygous
FH patients, early calcifications associated with chronic exposure to high LDL-C (cholesterol
burden, equivalent to cigarettes) and finally, the calcifying role of statins.
The early increase of LDL-C in patients with genetic forms of FH causes premature
cardiovascular damage. Investigators' hypothesis is that patients with FH have earlier
coronary atheroma (and thus calcifications and non-calcified plaques) due to exposure early
in life to high levels of LDL-cholesterol.
Description:
The CAC score has demonstrated very powerful predictive power, particularly in asymptomatic
populations.
1. The CAC score can:
1.1- Identify subjects with high cardiovascular risk According to prospective studies,
it is estimated that a CAC score> 400 is a CHD equivalent, with 10-year event rates
exceeding 20% in asymptomatic patients. Prospective studies in young patients with a
family history of cardiovascular disease or dyslipidaemia showed a higher risk of
cardiovascular disease in those with a CAC score of 0.
1.2- Identify subjects with low cardiovascular risk Regardless of the presence of risk
factors, meta-analyses have repeatedly shown the high negative predictive power
associated with a CAC = 0. The absence of calcified plaque presents an extraordinarily
low risk at 10 years (1.1% at 1.7%) regardless of the number of risk factors Regardless
of the presence of risk factors, meta-analyses have repeatedly shown the high negative
predictive power associated with a CAC = 0 with an annual mortality rate of 0.87
compared to 1.92 in those with CAC between 1 and 10. Finally, recent studies have
questioned the indication of a statin in non-HeFH patients with CAC = 0.
Non-calcified plaques are not, by definition, detected by CAC tests and patients with
CAC = 0 may only exhibit soft, non-calcified plaques. The prevalence of these
non-calcified plaques in high-risk patients with acute coronary syndrome is 5% . The
prevalence in heHF patients is unknown.
2. Description of the population to be studied and justification of their choice.
Recruitment of patients with familial hypercholesterolemia will be carried out at the
Cardiovascular Prevention Unit of the Pitié-Salpêtrière Hospital and in the Cardiology
Department of Saint-Antoine Hospital. Patients will be included in the study when they
come for their usual consultation or as part of their cardiovascular assessment in day
hospitalization.
3. Brief description of the product (s) or experimental act (s)
The actions and blood tests added by the research are as follows:
Imaging: Coronary CT angiography with injection of iodinated contrast medium Biology:
Calculation of cholesterol burden Vitamin D and K, estradiol, Parathormone IL-1β, IL-6,
IL-11, IL-17 TGFβ1 TNFα,Genomic and proteomic analyses: Osteopontin (OPN), Osteocalcin,
Osteoprotegerin, Osteonectin Receptor activator of nuclear factor kappa-B ligand, Bone
morphogenetic protein 2 4 and 7, Human Bone metabolism simplicat Matrix Gla Protein MGP
4. Summary of foreseeable benefits and risks known to those who are suitable for research.
Individual risk
- Risks and physical constraints: patients will undergo a standard blood sampling for
lipid levels and other biochemistry dosages and the realization of an arterial carotid
and femoral ultrasound, as well as the coronary CT (with injection).
- Risks associated with the disease: there are no directly study-related risks of
worsening of any previous condition in relation to the current pathology in the
realization of this study. The increased cardiovascular risk associated with heFH is
represented mostly by coronary artery disease which is related to the increased lifelong
high cholesterol exposure.
- Risk of irradiation: study subjects wil lbe exposed to 2 - 5 mSv for the realization of
both CAC score and coronary CT.
- Risk linked to the venous draining of 36 mL of blood all in all: pain, bruise, vagal
faintness(malaise)
- Risks associated to the injection of iodized contrast agent: allergic reaction.
This pilot study will evaluate the prevalence of high CAC score in asymptomatic patients with
heHF. This will be a first step in improving knowledge and treatment of heHF since using the
CAC score, the investigators:
- Would identify the patients with increased risk to whom premature / aggressive
interventions are recommended.
- Would validate a new non-invasive marker of the coronary damage in this heterogeneous
population.
This project enters the wider frame of the premature ageing of the cardiovascular system with
consequences on the development of cardiovascular complications such as the vascular
calcifications. It was designed to highlight subclinical changes of the vascular tree to
improve the treatment of the heHF and prevent the long-term complications of this disease.
This project could help to identify new markers of myocardial and arterial dysfunction to
propose an adapted prevention. The evaluation of the efficiency of medicine can be envisaged
at the end of this study and will be encouraged by the strictly non invasive nature of the
procedure as well as by its excellent reproducibility. It will also help to define strategies
of prevention to improve the management of heHF.
The results will be broadcasted by means of scientific publications and of presentations in
conferences or congress.
